Young Kim Robert's most recent trade in 4D Molecular Therapeutics Inc was a trade of 92,300 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 6, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
4D Molecular Therapeutics Inc | Robert Young Kim | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 92,300 | 92,300 | - | - | Stock Option (Right to Buy) | |
4D Molecular Therapeutics Inc | Young Kim Robert | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2024 | 12,000 | 138,000 | - | - | Stock Option (Right to Buy) | |
4D Molecular Therapeutics Inc | Young Robert Kim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.66 per share. | 05 Feb 2024 | 12,000 | 13,595 | - | 18.7 | 223,920 | Common Stock |
4D Molecular Therapeutics Inc | Young Robert Kim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.05 per share. | 05 Feb 2024 | 12,000 | 1,595 | - | 30.1 | 360,600 | Common Stock |
4D Molecular Therapeutics Inc | Young Robert Kim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.78 per share. | 05 Feb 2024 | 6,000 | 7,595 | - | 15.8 | 94,680 | Common Stock |
4D Molecular Therapeutics Inc | Kim Young Robert | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 05 Feb 2024 | 6,000 | 7,595 | - | 8.0 | 48,240 | Common Stock |
4D Molecular Therapeutics Inc | Kim Young Robert | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2024 | 6,000 | 64,000 | - | - | Stock Option (Right to Buy) | |
4D Molecular Therapeutics Inc | Young Robert Kim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2024 | 6,000 | 54,000 | - | - | Stock Option (Right to Buy) | |
4D Molecular Therapeutics Inc | Kim Young Robert | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.05 per share. | 05 Feb 2024 | 6,000 | 1,595 | - | 30.1 | 180,300 | Common Stock |
4D Molecular Therapeutics Inc | Robert Kim Young | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.05 per share. | 05 Feb 2024 | 6,000 | 1,595 | - | 30.1 | 180,300 | Common Stock |
4D Molecular Therapeutics Inc | Kim Young Robert | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.05 per share. | 05 Feb 2024 | 552 | 1,043 | - | 30.1 | 16,588 | Common Stock |
4D Molecular Therapeutics Inc | Young Robert Kim | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2023 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) |